In vivo isolation of circulating tumor cells from peripheral blood of patients with lung cancer by using a structured antibody-coated nanodetector: An explorative mono-center non-randomized blinded trial

GILUPI GmbH (Germany)0 个研究点目标入组 60 人开始时间: 2012年2月6日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Subjects suffering from lung cancer (diagnosed), they are qualified for radical operation of the tumor
•2. Age = 18 years
•3. Results of laboratory tests are in the area that the patient is qualified to perform an operation
•4. Written informed consent
•5. For control group: Five subjects are non-cancer patients

•1. Medical history revealing psychiatric disease or any other serious diseases
•2. Participating in other clinical trials
•3. Any findings in physical examination that would in the opinion of the investigator make participation unsafe for the volunteer
•4. Any presence or history of allergy (including hay fever)
•5. Any history of anaphylactic or anaphylactoid
•6. Auto immunological diseases: Anti-phospholipid antibody syndrome (lupus anticoagulant), Goodpasture's syndrome, lupus erythematosus, relapsing polychondritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, antineutrophilic cytoplasmic antibody (ANCA)
•7. Immuno deficiencies: X-linked aggamaglobulinaemia (XLA), severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), selective IgA deficiency
•8. Known infection with: hepatitis A, B and C, human immunodeficiency virus (HIV), herpes simplex virus (HSV), cytomegalovirus (CMV), syphilis, toxoplasmosis, tuberculosis; known illegal drug abuse
•9. Changes in laboratory values with negative performance for surgery
•10. Signs of inflammation reactions

发起方

GILUPI GmbH (Germany)